INTERNATIONAL PATENT: WELNX COMPANY INC. FILES APPLICATION FOR "USE OF CD38 INHIBITORS FOR REDUCING TH2 INFLAMMATION"

GENEVA, Jan. 3 -- WELNX COMPANY INC. (200-4388, rue Saint-DenisMontreal, Quebec H2J 2L1) filed a patent application (PCT/CA2025/050888) for "USE OF CD38 INHIBITORS FOR REDUCING TH2 INFLAMMATION" on Jun 25, 2025. With publication no. WO/2026/000074, the details related to the patent application was published on Jan 02, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): TREMBLAY, Guy Fernand Andre (10400 avenue AudoinMontreal-Nord, Quebec H1H 5E4)

Abstract: Methods for reducing TH2 inflammation and for treating or preventing a TH2 inflammation-associated condition in a subject comprising adminis...